Search Results

Your search for Mikkael A. Sekeres, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 2023 ASH

Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?

Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781,...

lymphoma

myelodysplastic syndromes

By Richard M. Stone, MD / 2014 ASH Annual Meeting

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North...

Apr

Today In Oncology

Search Results

Your search for Mikkael A. Sekeres, MD matches 2 pages

Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?

Richard M. Stone, MD, on the SWOG S1117 Study

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer